Floatz logo

Empagliflozin

Ascites

Stanford UniversitySmall moleculePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Ascites cohort.

Asset / SponsorPhaseRating
Tolvaptan
Konkuk University Medical Center
Phase 4BBB
NORMAL HUMAN SERUM ALBUMIN
Centro Medico Issemym
Phase 4BBB
FUROSEMIDE
University of Palermo
Phase 4BB
Rifaximin
Centre Hospitalier Universitaire de Besancon
Phase 4BB
Spironolactone
University of Padova
Phase 4BB

View all 36 →

Same molecule, other indications

Empagliflozin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
Hypoglycemic AgentsDormant
BBB
Indicative ·
75 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →